Previous studies showed that adrenomedullin (AM) could be a promising molecular imaging agent for the pulmonary circulation with abundant specific binding sites at the pulmonary vascular endothelium. The purpose of this work was to design an AMbased compound that encompasses the desired imaging properties without arising safety issues for clinical applications. 
Introduction
On one hand, pulmonary embolism (PE) is a potentially lethal lung perfusion defect that commonly develops in patients suffering from deep vein thrombosis (1) . On the other hand, pulmonary hypertension (PH), a disorder with various etiologies, leads in its most severe forms to right ventricular failure and death (2) . Diagnosis of these pathologies is challenging because patients often present with a non-specific symptom, shortness of breath. Currently, nuclear imaging of the pulmonary circulation can be achieved through the use of 99m Tc-albumin macro-aggregates, particles that are trapped in the microvasculature due to their size (10-150 µm) in proportion to the regional blood flow (3) . However, this technique lacks the ability to detect functional perfusion defects while uncovering of small blood vessel blockade is limited. Moreover, this tracer blocks pulmonary blood vessels in subjects with an already compromised pulmonary circulation while increasing the potential infectious risk because it is prepared from human albumin. We have recently shown that adrenomedullin (AM) is a very promising molecular lung imaging tool for the diagnosis of pathologies such as PE and PH (4, 5) . AM, a peptide from the calcitonin family, allows specific lung imaging through binding with its specific receptor AM1 (CRLR/Ramp2), expressed in high density in pulmonary vessels (6, 7) . Enhanced imaging efficiency can be associated with cell internalization after receptor activation by its agonist (8,9) but this process is also correlated with inherent biological activity. 4 Conversely, antagonists do not evoke cellular activation upon receptor binding while being able to bind with uniform affinity to the total pool of receptors (10, 11) .
AM is a 52-amino acid multifunctional regulatory peptide widely distributed and acting mainly in the cardiovascular system where it is classically described as a vasodilator (12) . Previous structure-activity relationship studies have demonstrated that truncation of the N-terminal stretch while keeping the cyclic structure formed by a disulfide bridge between residues 16 and 21 generated agonists, such as AM and AM , with similar affinity to the full length peptide (13) . Further truncation at the N-terminus to remove the ring structure yields the only fully characterized human AM antagonist, i.e. AM while removal of the C-terminal amino acid greatly diminishes binding affinity and peptide activity (13, 14) . Interestingly, analogs composed only of the ring structure, i.e. AM (15) (16) (17) (18) (19) (20) (21) (22) and AM (16) (17) (18) (19) (20) (21) , increase systemic arterial blood pressure (15) but AM and AM(1-40) were unable to displace 125 I-AM in a dog lung homogenate binding experiment (6) . Moreover, linearization of the full-length peptide resulted in a loss of affinity (6, 13) . Finally, although AM is quite a long peptide, incorporation of a radionuclide can affect its binding ability and therefore AM-derived nuclear imaging tools should favour radiolabeling at the N-terminus of the peptide (16).
AM ) is an antagonist having 10 times less affinity for its receptors than AM(13-52) in competition displacement experiments, but with higher selectivity for 5 AM1 over AM2 (CRLR/Ramp3) (6, 14) . Thus, this peptide appeared has a good starting point to generate new AM antagonists suitable for nuclear lung imaging. Such an analog would enable pulmonary microcirculation imaging without any side effects on blood pressure. Furthermore and as pointed out for AM, such a molecule would not only be valuable to detect perfusion defects but could also allow the detection of early endothelium related deficiencies such as PH.
In this article, we describe the design, synthesis and characterization of PulmoBind, an AM-based analog for pulmonary circulation imaging. This new molecular lung imaging tool shows good binding affinity, high This molecule could offer the possibility not only to detect large pulmonary vessel blockade such as PE, but also allow detection of anatomical and, potentially, functional pulmonary microcirculatory disorders caused by the various forms of PH.
Thus, PulmoBind could provide an efficient, safe and non-invasive method to probe the status of the pulmonary circulation.
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MATERIALS AND METHODS
All animal experimental procedures were performed in accordance with regulations and ethical guidelines from the Canadian Council for the Care of Laboratory Animals, and received approval by the animal ethics and research committee of the Montreal Heart Institute.
AM Derivative Synthesis and Purification
AM-derived peptides were synthesized and purified as described previously (6) . The N-Fmoc-amino-d-Polyethylene glycol (PEG) 4 -acid used as a spacer in the peptide synthesis was purchased from Quanta Biodesign Ltd. (Powell, OH, USA).
Disulfide bond formation to give cyclic derivatives was performed with an overnight air oxidation after dissolution of the linear peptide in an aqueous solution (pH 8.8) at a concentration of 0.1 mg/mL. Peptides were purified by reversed phase-HPLC.
Amino acid sequences of synthesized peptides are given in Table 1 along with purity of final products and molecular mass as evaluated by Maldi-Tof mass spectrometry (Voyager DE, Applied Biosystems, CA, USA). 
Tc-Labeling
Linear AM was radiolabeled through its cysteine residues as previously described (5 TcO 4 (185-555 MBq) in a sodium chloride injection USP solution was added to the mixture. The mixture was kept at room temperature for 15 min and 1 mL of NaH 2 PO 4 0.1M (pH 4.5) was finally added. Radiochemical purity and labeling efficiency was assessed through instant thin layer chromatography on silica gel impregnated glass fiber paper (ITLC-SG) using acetone for dosage of free 
In vivo Biodistribution and Lung Uptake
Mongrel dogs (20- as a percentage of the total radioactivity injected.
Binding Assays
The binding ability of PulmoBind was evaluated in dog lung homogenates prepared as previously described (6) . Briefly, lungs were diced, homogenized and centrifuged at 49000 g at 4°C for 20min. Pellets were washed twice and nonhomogenized tissue was removed by gentle centrifugation (500 g, 5 min). Aliquots of the supernatant were kept at -80°C until used for binding assays. Binding experiments were based on protocols described in previous publications (6, 16) . The 
Hemodynamic Evaluation
Mongrel dogs (male and female) were used to study cardiovascular effects induced by cumulative i.v. injections of human AM(1-52), the agonist hAM(13-52), the antagonist hAM(22-52) and PulmoBind. Heart rate of anesthetized and ventilated animals was monitored with cutaneous electrocardiographic leads and a catheter installed in the right femoral artery was used to monitor blood pressure. Pulmonary artery pressure was evaluated using a Swan-Ganz catheter. Briefly, the catheter was introduced through the jugular vein. From this entry site, it was threaded by fluoroscopy through the right atrium of the heart, the right ventricle, and subsequently into the pulmonary artery until a wedge pressure tracing was noticed.
Then, Swan-Ganz catheter balloon was deflated; deflation was confirmed by reappearance of pulmonary artery pressure contours.
Dosimetry Evaluation
The PulmoBind tracer was injected to 7 dogs to estimate the mean biodistribution using whole-body scintigraphic images. Before peptide injection, a whole-body transmission scan was performed on the gamma-camera using a 57 Cobalt flood source. The injection syringe was measured prior to injection under the camera. Then, immediately after intravenous injection, dynamic acquisitions were recorded for a 30-min period and static whole body scans were performed at 35, 60
and 120 min after at a scan speed of 10 cm/min. The empty syringe was measured again to determine residual activity.
The biodistribution into organs with significant uptake was evaluated using MATLAB version 7.01 image analysis tools software. Dynamic and whole-body images were first corrected for radioactive decay. Regions of interest were drawn on each organ in anterior and posterior views and on the transmission map. Geometric means of each organ activity were performed and then corrected for average attenuation over the organ. Using syringe images data, results were converted to percentage of the total radioactivity injected.
These animal studies in dogs were performed to get a first approximation of the expected radiation dose absorbed in human subjects. Despite differences between animal and human pharmacokinetic behaviours, an extrapolation process was used to estimate human dosimetry from the calculated dog biodistribution. To compensate the physiological time difference between species, allometric scaling was applied to the biodistribution curves assuming human physiological time to be 1.19
time slower than the canine one (fourth root of the mass ratio) (17) . Individual organs and whole-body-time-activity curves were fitted using the OLINDA software v.1.0 (18) . Target organ absorbed radiations were calculated for a 73.7kg standard man and a 56.9kg standard woman models using the same software.
Lung perfusion in pulmonary arterial hypertension
Male Sprague Dawley rats weighting between 200-225 g received a 0.5 mL intraperitoneal injection of either 0.9% saline (n=4) or 60 mg/kg monocrotaline (MCT, n=4). Five weeks later, rats were anesthetized for hemodynamic measurements and nuclear medicine experiments with PulmoBind as previously described (4).
Statistics
Statistical analyses were assessed using the Prism 4.0 software (GraphPad, San Diego, CA, USA) with an unpaired Student t-test or a One Way Anova as indicated in the figure legends.
RESULTS
Synthesis
AM analogs were designed in a simple and straight forward manner based on our previous results using AM as a 99m
Tc-labeled imaging agent and known structureactivity relationships. In fact, linear AM had been directly labeled through its free cysteine residues and purified with a SepPak cartridge to obtain a final product of (5). However, the initial yield of with Cys(Acm) residues, which cannot form a disulfide bridge since their sulfhydryl moieties are blocked by an Acm group, to verify the impact of cyclization on lung uptake and the influence of cysteine residues in the labelling process.
All peptide syntheses yielded only one major product that was isolated by RP-HPLC and confirmed to be the desired AM analog by Maldi-Tof mass spectrometry analysis. Formation of the disulfide bond was monitored by analytical RP-HPLC, the 13 cyclized peptide having a shorter retention time than its linear counterpart (results not shown).
99m
Tc-Labeling
As expected, the introduction of a chelating moiety greatly improved the 99m
Tc-labeling yield of AM analogs as compared to linear AM (Figure 1 ). In fact, labeling of AM through its free cysteine residues resulted, on average, in 65% of 99m
Tc-AM whereas the labeling yield was higher than 80% when using the tetrapeptide as the 
In vivo Biodistribution and Lung Uptake
Since very satisfying 99m Tc-labeling yields were obtained with the three AM analogs, their lung uptake ability was evaluated in anesthetized dogs. Purified labeled compound 1, 2 or 3 (radio was injected i.v. and a lung dynamic acquisition was performed. All three compounds showed reduced lung uptake as compared to AM (Figure 2 ). However, compound 2 had a lung first-pass comparable to that observed with AM (around 75% of the injected dose) rapidly followed in the first minute by a 40% uptake plateau maintained for up to 1 h ( Figure 2 ). As for compounds 1 and 3, initial lung uptake was considerably reduced (around 55% of the injected dose) and continuously cleared 14 from the pulmonary circulation ( Figure 2) . Interestingly, at 30 min post-injection, compound 2 had a very low heart uptake (3.1 ± 0.3%) even lower than AM (4.9 ± 1.0%) although not significantly different, an important asset to obtain good lung imaging ( Figure 3) . Moreover, liver uptake for compound 2 was comparable to what was observed with AM. Thus, with a liver uptake of less than 10% (8.2 ± 0.8%) of the injected dose, a lung uptake at least 5 times as high as heart uptake and a lung retention lasting up to 1 h, compound 2 appeared as a good candidate for lung imaging ( Figure 4 ). Further analyses were performed to characterize this compound, renamed PulmoBind.
Binding Assays
To further characterize this new lung imaging agent, binding assays were performed on dog lung homogenates using Figure 5C ).
Hemodynamic Evaluation
AM is a known vasodilator. When injected i.v. in anesthetized dogs, AM produced a drop in mean arterial blood pressure (MAP) with increasing doses that was accompanied by an elevation in heart rate (HR) ( Figure 6A ). Similarly, the truncated AM agonist, hAM(13-52), generated decreases in MAP proportional to the increased dose of peptide injected. Noteworthy, the accompanying increase in HR was less pronounced than that observed with AM, although the drop in MAP was similar ( Figure 6B ). When cumulative doses of hAM(22-52), a specific AM antagonist, were injected, no changes in MAP nor HR were observed even at a dosage equal to 50 times the initial injection ( Figure 6C ). In a similar manner, cumulative i.v. injections of PulmoBind, which is derived from the latter antagonist, did not produce significant variations of MAP and HR, suggesting that this new lung imaging agent also acts as an antagonist ( Figure 6D ). Finally, mean pulmonary artery pressure (MPAP) did not vary significantly following injections of hAM(22-52) or PulmoBind, and was within expected values.
Dosimetric Analysis
A dosimetric analysis of PulmoBind is shown in Table 2 . This analysis is extrapolated to human using the biodistribution obtained from dogs. The analysis reveals a favourable profile with rapid elimination of the tracer into urine and digestive tract with kidneys receiving the highest radiation dose (0.034mGy/MBq; Table 2 ). Total effective dose was evaluated under allometric scaling to be 0.0075 and 0.0094 mSv/MBq for a man and woman respectively after 2h (Table 3) .
Pulmonary arterial hypertension model
As shown in figure 7 , the in vivo biodistribution revealed a markedly reduced lung uptake of PulmoBind from 12 ± 2% ID in controls to 4 ± 1% in PAH, P<0.001.
DISCUSSION
Nuclear medicine offers clinicians novel avenues for diagnosis and therapy of various pathological conditions with non-invasive and rapid techniques. In fact, success of nuclear medicine relies on the effectiveness of radiopharmaceutical compounds. These compounds, consisting of a target-specific moiety and a radionuclide, must be well designed and finely tuned to attain the desired results for a particular purpose. Because of their inherent specificity, antibodies are biomolecules of interest to generate pharmaceutical compounds. However, their poor pharmacokinetics and their tendency to evoke an immunogenic response (20) limit their effectiveness. On the other hand, peptides are also highly specific biomolecules that proved to be useful targeting moieties to generate therapeutic or imaging agents (21, 22) Incorporation of this peptide chelating moiety greatly improved the labeling yield without any significant difference between the 3 compounds synthesized (Figure 1) . A difference appeared when lung uptake was evaluated. As a matter of fact, the presence of a cyclic structure proved to be crucial for efficient lung uptake because just 10 min after injection, about 20% of the linear AM analogs (compounds 1 and 3)
remained in the lung whereas more than 40% of AM and the cyclic analog (compound 19 2) were retained in the organ, with maintenance of this activity even after 30 min (Figure 2 ). These results are in accordance with structure-activity relationship studies of peptides belonging to the calcitonin family. Circular dichroism analyses of AM demonstrated that the peptide possesses a structure composed of 28% -helix and 18% -sheet. Interestingly, the antagonist AM(22-52) shares these structural features (14) . However, the ring structure composed of 6 residues linked by a disulfide bridge is a common characteristic to all calcitonin peptide family members despite their low sequence homology and it has been shown to be important for proper binding and subsequent signalling (13, 26) . Moreover, amino acid substitution within the ring structure does not seem to alter potently the peptide biological activity (26) .
Therefore, combining AM(22-52) to a flexible ring structure composed of 2 cysteine residues linked by a PEG spacer to substitute the 6 residues generated a molecule encompassing all important AM structural features to ensure proper receptor binding while avoiding a biological response. In fact, the use of a PEG 4 spacer allowed appropriate spacing without introducing reactive or sensitive chemical groups or increasing too much the hydrophobicity of the molecule. Furthermore, the chelating moiety was added at the N-terminus of the peptide since it was demonstrated that labeling of the peptide at any other position could affect receptor interaction (16) .
Results from our binding study correlate furthermore with AM structure-activity relationships. Indeed, AM was shown to have a Kd of 0.17 ± 0.07 nM on dog lung homogenates (16) while PulmoBind (compound 2) has a Kd of 2.6 ± 0.8 nM on the 20 same preparation ( Figure 5 ). It has to be pointed out that using the same conditions to evaluate binding, AM(22-52) had about 100 times less binding affinity than AM and even linear AM (reduced disulfide bridge) had markedly reduced affinity (6) . Thus, adding a cyclic structure to AM(22-52) to generate our PulmoBind analog has enhanced binding significantly. Moreover, the number of accessible binding sites appears to be higher for PulmoBind than AM since Bmax values are 2317 ± 320 fmol/mg ( Figure 5 ) and 1222 ± 148 fmol/mg, respectively (16) . This observation can be related to studies on somatostatin, corticotrophin releasing factor and bombesin demonstrating that radioactive ligand antagonists label more receptor binding sites than corresponding agonists (11, 27, 28) . Therefore, it appears that the slight binding affinity loss of PulmoBind is compensated by a higher number of accessible binding sites that allows a pulmonary circulation imaging similar to that observed with the full AM peptide labelled with When designing targeted imaging compounds, the goal is to obtain high tissue specificity with a high signal-to-noise ratio, appropriate pharmacodynamics and good pharmacokinetics. Injection of PulmoBind in anesthetized dogs generated a good lung image with low heart and liver uptake, an essential feature for pulmonary vasculature imaging, even 60 min after the injection (Figure 4 ). The lung kinetic profile of PulmoBind was characterized by an uptake plateau suggesting irreversible binding to its pulmonary receptor. As determined by our in-vivo biodistribution study,
PulmoBind was not only retained in pulmonary circulation but also in kidneys ( Figure   3 ). As a matter of fact, labeling of kidneys and bladder were higher than other tissues at later time points with a concomitant decrease in lung, heart and liver uptake indicating that the molecule was eliminated mainly through renal excretion. This clearance route had also been observed with AM labeled with 99m Tc (5). Thus, PulmoBind appears to offer good pulmonary circulation imaging properties, without adverse hemodynamic effects and with urinary elimination, qualities making it a very promising compound for clinical use. However, this elimination route is associated with our finding that kidneys are the critical organ in terms of radiation dose.
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Moreover, the urinary tract being in close proximity to radiation sensitive tissues such as reproductive organs could be a safety concern but our dosimetry analysis revealed that testes and ovaries were receiving the least radiation among the evaluated organs (Table 2 ) and even the kidneys were submitted to doses lower than other critical organs identified with clinically used Tc-radiopharmaceuticals (Table 3 ). Finally, with the proposed injected activity (185-555MBq), the total effective radiation dose 
